Apex BiotechnologyTPE:1733 -0.17%81 Quick Ratio is 2.57 as of Dec. 2025, which is 33% above its 10-year median of 1.93. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Apex Biotechnology ranks worse than 59.52% on this metric.
Apex Biotechnology has a quick ratio of 2.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for Apex Biotechnology's Quick Ratio or its related term are showing as below:
TPE:1733'
s Quick Ratio Range Over the Past 10 Years
Min: 1.03 Med: 1.93 Max: 2.67
Current: 2.57
During the past 13 years, Apex Biotechnology's highest Quick Ratio was 2.67. The lowest was 1.03. And the median was 1.93.
TPE:1733's Quick Ratio is ranked worse than 59.52% of 1408
companies
in the Biotechnology industry
Industry Median: 3.6
vs TPE:1733: 2.57
Apex Biotechnology (TPE:1733) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Apex Biotechnology Quick Ratio Related Terms
Apex Biotechnology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Apex Biotechnology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Apex Biotechnology's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Quick Ratio of 2.57 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Apex Biotechnology and its competitors. This is 33% above median its historical median of 1.93. Over the past decade, Apex Biotechnology's Quick Ratio has ranged from 1.03 to 2.67. According to the industry distribution chart, Apex Biotechnology ranks #838 out of 1408 companies in the Biotechnology industry, placing it in the top 59.5%.
Is Apex Biotechnology's Quick Ratio too high?
Apex Biotechnology's current Quick Ratio of 2.57 is 33% above median its 10-year median of 1.93. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 2.67. The Biotechnology industry median Quick Ratio is 3.60. Apex Biotechnology's value of 2.57 is 28.6% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #838 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #838 out of 1408 companies for Quick Ratio. This places Apex Biotechnology in the lower half of its industry. The industry median Quick Ratio is 3.60. Apex Biotechnology's value of 2.57 is 28.6% below this benchmark. Historically, Apex Biotechnology's own Quick Ratio has ranged from 1.03 to 2.67 over the past decade. While the company's 10-year median is 1.93 vs. the industry median of 3.60, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Quick Ratio of 2.57 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Quick Ratio is 2.57, which is 33% above median its own 10-year median of 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Quick Ratio is 2.57, which is 33% above median its 10-year median of 1.93 and 28.6% below the Biotechnology industry median of 3.60. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Quick Ratio is 2.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Quick Ratio: 2.57 (33% above median its 10-year median of 1.93)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 28.6% below the Biotechnology median (#838 of 1408)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
